These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
58 related articles for article (PubMed ID: 25185205)
1. Uveal melanoma therapy on the horizon? Cancer Discov; 2014 Sep; 4(9):OF6. PubMed ID: 25185205 [TBL] [Abstract][Full Text] [Related]
2. Tebentafusp (Kimmtrak) for uveal melanoma. Med Lett Drugs Ther; 2024 Jun; 66(1705):e107-e108. PubMed ID: 38905528 [No Abstract] [Full Text] [Related]
3. The Mayo Clinic experience with the use of kinase inhibitors, ipilimumab, bevacizumab, and local therapies in the treatment of metastatic uveal melanoma. Moser JC; Pulido JS; Dronca RS; McWilliams RR; Markovic SN; Mansfield AS Melanoma Res; 2015 Feb; 25(1):59-63. PubMed ID: 25396683 [TBL] [Abstract][Full Text] [Related]
4. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. Hochster HS; Uboha N; Messersmith W; Gold PJ; ONeil BH; Cohen D; Denlinger C; Cohen S; Leichman CG; Leichman L; Lenz HJ Cancer Chemother Pharmacol; 2015 Jan; 75(1):17-23. PubMed ID: 25322874 [TBL] [Abstract][Full Text] [Related]
5. Characterization, treatment, and outcome of uveal melanoma in the first two years of life. Yousef YA; Alkilany M Hematol Oncol Stem Cell Ther; 2015 Mar; 8(1):1-5. PubMed ID: 25300563 [TBL] [Abstract][Full Text] [Related]
6. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. Long GV; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Grob JJ; Chiarion Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JB; Hansson J; Utikal J; Ferraresi V; Kovalenko N; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; DeMarini DJ; Irani JG; Casey M; Ouellet D; Martin AM; Le N; Patel K; Flaherty K N Engl J Med; 2014 Nov; 371(20):1877-88. PubMed ID: 25265492 [TBL] [Abstract][Full Text] [Related]
11. MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. Angell TE; Lechner MG; Jang JK; LoPresti JS; Epstein AL Clin Cancer Res; 2014 Dec; 20(23):6034-44. PubMed ID: 25294906 [TBL] [Abstract][Full Text] [Related]
12. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Irving J; Matheson E; Minto L; Blair H; Case M; Halsey C; Swidenbank I; Ponthan F; Kirschner-Schwabe R; Groeneveld-Krentz S; Hof J; Allan J; Harrison C; Vormoor J; von Stackelberg A; Eckert C Blood; 2014 Nov; 124(23):3420-30. PubMed ID: 25253770 [TBL] [Abstract][Full Text] [Related]
13. c-MET expression in primary and liver metastases in uveal melanoma. Gardner FP; Serie DJ; Salomao DR; Wu KJ; Markovic SN; Pulido JS; Joseph RW Melanoma Res; 2014 Dec; 24(6):617-20. PubMed ID: 25211165 [TBL] [Abstract][Full Text] [Related]
14. Genetic determinants of uveal melanoma. Kaur J; Malik MA; Gulati R; Azad SV; Goswami S Tumour Biol; 2014 Dec; 35(12):11711-7. PubMed ID: 25296731 [TBL] [Abstract][Full Text] [Related]
15. Profile of selumetinib and its potential in the treatment of melanoma. Kim DW; Patel SP Onco Targets Ther; 2014; 7():1631-9. PubMed ID: 25278770 [TBL] [Abstract][Full Text] [Related]
16. Selumetinib for the treatment of cancer. Ciombor KK; Bekaii-Saab T Expert Opin Investig Drugs; 2015 Jan; 24(1):111-123. PubMed ID: 25385055 [TBL] [Abstract][Full Text] [Related]
17. Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation. Grasso S; Tristante E; Saceda M; Carbonell P; Mayor-López L; Carballo-Santana M; Carrasco-García E; Rocamora-Reverte L; García-Morales P; Carballo F; Ferragut JA; Martínez-Lacaci I Neoplasia; 2014 Oct; 16(10):845-60. PubMed ID: 25379021 [TBL] [Abstract][Full Text] [Related]
18. ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors. Goetz EM; Ghandi M; Treacy DJ; Wagle N; Garraway LA Cancer Res; 2014 Dec; 74(23):7079-89. PubMed ID: 25320010 [TBL] [Abstract][Full Text] [Related]
19. Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancer. Okamoto I; Miyazaki M; Takeda M; Terashima M; Azuma K; Hayashi H; Kaneda H; Kurata T; Tsurutani J; Seto T; Hirai F; Konishi K; Sarashina A; Yagi N; Kaiser R; Nakagawa K J Thorac Oncol; 2015 Feb; 10(2):346-52. PubMed ID: 25299232 [TBL] [Abstract][Full Text] [Related]